Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. - Wikidata - awgldk - TriplyDB

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

http://www.wikidata.org/entity/Q33814916

about

An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma Targeted Therapy in Biliary Tract Cancers Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression.Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.Surgical resection of solid gallbladder adenocarcinoma presenting as a large mass: report of a case Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread.Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.HER2/neu-directed therapy for biliary tract cancer.Mutation profiling in gallbladder cancer in Indian population Molecular biology of gallbladder cancer: potential clinical implications Molecular genetics and targeted therapeutics in biliary tract carcinoma.Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials Meta-signature of mutated genes in gallbladder cancer: evidence based high throughput screening assays.Current therapy and future directions in biliary tract malignancies.A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Advances in the management of biliary tract cancers New and emerging treatment options for biliary tract cancer.New Horizons for Precision Medicine in Biliary Tract Cancers.KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers.Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.Current biologics for treatment of biliary tract cancers.Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma.Microsatellite instability in gallbladder carcinoma.Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients.Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer.Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.

P2860

Q26784091-A8B04E2A-99A7-4D77-98DE-41015D3CFF97 Q26798443-BA854C92-722B-4A3B-A07E-26E546F0F91D Q27002547-AE21271A-2DB1-4D92-845C-0B3A5473B61B Q27852856-C03325CC-9EA1-448A-860A-7B6CB93138A7 Q33556032-A04B506B-D578-4040-9167-92C17A0B3E1A Q33721146-9A84B030-A733-472B-A19A-0D9D783F99E1 Q33757122-C68CA184-69D3-40AB-A384-1D556FADD90C Q34414476-B2753A2C-98FF-43B7-A026-FFCF92DC1D5D Q35035238-3184317A-3677-4484-81CA-DA61B993C1B2 Q35083816-1143A154-F2C3-4AE6-A79B-9AD4ED6B37DE Q35153098-41EE3C28-17D3-498B-B867-622A41C9B7FD Q35179333-790F4B4A-A403-409D-BCDD-9BE6357A87A0 Q35705307-3CE6BEE7-E236-4F60-8CAB-D596CC054877 Q35748129-847E3015-8DA0-4A6E-AD7E-23DE3B365C78 Q35756096-1DDB951E-4B05-4360-8880-A8ABB75E70BA Q36352240-44D8637A-7712-4891-9F0D-D9DA215777F6 Q36488070-0C3507D4-E280-44FD-B817-64143599DE45 Q36501683-8B779D73-E4C4-40CA-B89B-1AE933A16699 Q36972551-6050558D-FEDC-40F3-84F1-961A137FB28C Q36984860-40698FF6-5F32-46EB-854C-C797349F9FE1 Q37027240-F80E7449-DFFA-442D-9B0A-B3AD284ADE37 Q37161293-2B28E8A6-6808-430E-9BEE-04900A5F8569 Q37639577-03BC1381-5D4B-4849-86F3-910347894E01 Q37706353-17E01C9B-2125-4587-A8FC-82D431172386 Q37719383-D101D090-95A2-4A69-A579-1CEA3BD2B7AA Q38082318-0F437887-4831-4419-B54A-4668743009E3 Q38160836-EA99762E-EFE9-48BA-8EEF-DAF4B03C4125 Q38619219-6249AFAD-AB8D-4152-8E0F-98FBF2CA1E65 Q39070009-1BADA7C8-D0DB-4B01-A96A-410BACCE2B3D Q39240982-8792A6DE-C1D8-4C6D-9CFF-86994C38F8A1 Q39289707-E8BBEC5A-8AC3-498F-8C02-2BB15AA8DF53 Q39453572-565E4B3C-89FD-47C8-9393-06B552F2F930 Q40914280-7FA22E7F-397C-4D97-B742-1C235DA974B6 Q41438298-EA6D1A37-326B-48C3-9E77-E896C5BCAE39 Q41545847-A747344A-C6CC-4FB0-93F9-886A4D9A1CF2 Q41582290-FC4B4073-065E-4E0B-9C50-2902A52FF4D5 Q42045560-CB01CDFD-8C1B-45E4-B90F-4AEB72250D1A Q45346288-E379159E-8012-4041-98E9-085E2BBFD5B3 Q49952154-FE1EA640-C4CB-4CE5-A165-B5C16646CD01 Q50967762-9290BA56-9194-4C58-93C9-A39CF5501AEE

P2860

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

http://www.wikidata.org/entity/Q33814916

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@ast

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@en

type

label

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@ast

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@en

prefLabel

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@ast

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@en

P1433

Q33814916-400D64F7-111E-4E55-B74B-EE222C669D74

P1476

Q33814916-10166904-3B00-4D98-9596-FF1406286894

P2093

Q33814916-2FF68E62-6AAF-4E93-9A58-A839A417BAD7

Q33814916-516D2286-D3A8-44CE-9A77-95D3FF9AF121

Q33814916-533FC0A9-6582-42F7-A0AB-CA8BAB1BA198

Q33814916-6B4AA52A-8DDF-4B73-A01A-D224C75CC3A6

Q33814916-96B644EC-6645-45A3-9367-E65E1307FECC

Q33814916-B8203BAF-80DE-4B36-B7CB-14F123125ABA

Q33814916-C3485469-DF72-4ABB-92AC-BBF32CD1EB3A

Q33814916-CACEB4A9-7AF0-4756-9904-A5B5217414ED

Q33814916-CEF2065B-353C-4604-84CA-D28F2F306E07

Q33814916-DF30AD0C-CD1D-4948-B989-DF5FB88CCA63

P2860

Q33814916-061CFB61-D81E-4E4E-BEB8-BCDD05622284

Q33814916-0FA3962C-1629-46D1-8A86-B35FA3E35E5B

Q33814916-10BDD8A3-B5D2-4410-8B6E-25A004BF8D3F

Q33814916-11D161AF-3951-4A7C-BF8B-1C2275476C79

Q33814916-1F1C5B9C-42FB-4D65-953A-C42D3B453EBB

Q33814916-2A48446D-67C2-4509-A7E5-B92DC715535F

Q33814916-45DD488E-4B8C-473D-9FAD-FD03A39DE64A

Q33814916-47E17B63-C95A-4834-8EA4-449B59A5CB8E

Q33814916-519FBAF0-A9FB-4808-AC34-E1902A9C35FA

Q33814916-57FB019F-A625-4287-89F9-1F19745A88BD

P2888

Q33814916-24D8861D-BD22-4C36-B0A1-AF28B02A9FD8

P304

Q33814916-2787BD9A-C4F6-4EAD-8B22-F98C8EFBDB76

P31

Q33814916-B1CDC289-9272-49D1-99F9-4F96C7B90135

P356

Q33814916-65126586-468D-473A-9FB5-001012248B94

P407

Q33814916-EDBCC690-F3CE-4544-B1C9-353BA44644EA

P478

Q33814916-4D64A8F7-0C11-4BE6-B89B-8AE4B768EFA3

P50

Q33814916-EE491FB7-FCD3-45D7-93F7-593AA99C7D7B

P577

Q33814916-E1948F7F-3AF7-47D5-A0ED-BB7A0E024E8C

P5875

Q33814916-64DC9AE1-85A5-48A8-A29A-D896B513DE49

P6179

Q33814916-C912AAAB-99C4-4BB1-9E38-3621F22AA42F

P698

Q33814916-D8958CD8-6367-4959-9D0D-21D57D4D8310

P932

Q33814916-D56F5AA0-3E1E-4034-9DE8-8E1110042CB2

P356

1471-2407-11-60

P1433

P1476

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

@en

P2093

Afamefuna Nduaguba

http://www.w3.org/2001/XMLSchema#string

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Aram F Hezel

http://www.w3.org/2001/XMLSchema#string

Cristina Ferrone

http://www.w3.org/2001/XMLSchema#string

Gregory Y Lauwers

http://www.w3.org/2001/XMLSchema#string

Laura E Macconaill

http://www.w3.org/2001/XMLSchema#string

Nabeel Bardeesy

http://www.w3.org/2001/XMLSchema#string

Sarah M Kehoe

http://www.w3.org/2001/XMLSchema#string

Stephanie M Zimmerman

http://www.w3.org/2001/XMLSchema#string

Vikram Deshpande

http://www.w3.org/2001/XMLSchema#string

P2860

Profiling critical cancer gene mutations in clinical tumor samples

Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

Genetics of biliary tract cancers and emerging targeted therapies.

P2888

1471-2407-11-60

P304

60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-60

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Nabeel Bardeesy

P577

2011-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49819637

http://www.w3.org/2001/XMLSchema#string

P6179

1043717738

http://www.w3.org/2001/XMLSchema#string

P698

21303542

http://www.w3.org/2001/XMLSchema#string

P932

3045359

http://www.w3.org/2001/XMLSchema#string